미국의 분자진단 시장 규모, 점유율, 동향 분석 보고서 : 질병별, 최종 용도별, 부문별 예측(2023-2030년)

U.S. Molecular Diagnostics Market Size, Share & Trends Analysis Report By Disease (Healthcare-associated Infections, Respiratory), By End-use (Hospital Core Laboratory, Decentralized Test Sites), And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,401,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,813,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,637,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

미국 분자진단 시장의 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 미국 분자진단 시장 규모는 2023년부터 2030년까지 CAGR 4.82%를 기록하며 2030년 84억 6,000만 달러에 달할 것으로 예상됩니다.

시장 성장의 배경에는 바이러스 및 박테리아의 조기 및 신속한 검출과 같은 분자진단 검사 도입의 이점에 대한 인식이 높아지고 있기 때문입니다. 또한, 잘 확립된 의료 부문과 유리한 상환 정책으로 인한 접근 용이성은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

또한, 업계 선두 기업들은 분자진단 기술의 기술적 진보에 투자하여 인력을 절감하고 즉각적인 결과를 얻을 수 있는 솔루션을 개발하고 있습니다. 예를 들어, QIAGEN은 진단 실험실 적용을 위해 EZ2 Connect MDx 플랫폼을 출시했습니다. 이 플랫폼은 고도의 자동화 기능을 갖추고 있으며, 24개의 시료에서 RNA와 DNA를 30분의 처리 시간으로 정제할 수 있습니다.

신속 검출 분석의 신흥국 시장 개척이 시장 성장을 뒷받침할 것으로 예상됩니다. 이러한 검사는 의사결정을 가속화하고 분산형 검사의 처리 시간을 단축함으로써 시장에 혁명을 일으켰습니다. 많은 기업들이 분석 및 분자진단 시스템을 개발하고 있으며, Qiagen의 임균, 클라미디아, 트라코마티스 진단용 Digene HC2 GC-ID DNA 검사, Danaher(Cepheid)의 마이코플라즈마 제니탈륨 진단용 마크로라이드 내성 확인 ResistancePlus MG FleXible은 이러한 제품 중 하나입니다.

Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc, Hologic Inc, BD 등 시장의 주요 기업들은, 제품 보급을 강화하고 고객 기반을 확대하기 위해 다양한 전략을 채택하고 있습니다. 예를 들어, 2023년 1월 써모피셔 사이언티픽과 아스트라제네카는 타그리소의 혈액 기반 및 고형 조직 동반 진단 테스트를 개발하기 위해 제휴를 맺었습니다.

COVID-19의 팬데믹은 코로나바이러스를 감지할 수 있는 신속하고 새로운 진단키트 개발을 촉진하여 업계에 긍정적인 영향을 미쳤습니다. 그 결과, 감염성 질환 분야에서 사업을 운영하는 주요 시장 진입 기업의 수익이 증가했습니다. 예를 들어, 써모피셔 사이언티픽(Thermo Fisher Scientific)은 2021년 4월에 진단 키트에 대한 수요 증가로 150%의 매출 성장을 보고했습니다. 그러나 이 지역에서는 백신 접종의 보급이 확대되고 있어 예측 기간 동안 COVID-19 검사에 대한 수요가 감소할 것으로 예상됩니다.

미국 분자진단 시장 보고서 하이라이트

• 질환별로는 호흡기질환 분야가 2022년 시장을 주도했습니다. 이러한 성장은 호흡기 감염증의 유병률 증가와 감염증의 진단 및 치료를 위한 진단 검사의 가용성에 대한 인식이 높아졌기 때문입니다.
• 최종 용도별로는 병원 핵심 검사실이 2022년 가장 큰 점유율을 차지할 것으로 예상되며, MRSA, 황색포도상구균(SA), 엔테로바이러스와 같은 감염성 질환의 유병률 증가로 인해 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 주요 업계 기업들은 신제품 출시, 제휴, 인수, 사업 확장 등 다양한 전략을 채택하여 제품 보급을 강화하고 더 많은 소비자 기반을 확보하기 위해 노력하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 분자진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 보급과 성장 전망 매핑
• 업계의 밸류체인 분석
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 미국의 분자진단 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 주요 거래와 전략적 제휴 분석
  • 시장 진출 전략

제4장 미국의 분자진단 시장 : 질환별 추정·동향 분석

• 시장 규모, 예측 및 동향 분석, 2018년에서 2030년까지

제5장 미국의 분자진단 시장 : 최종 용도별 추정·동향 분석

• 시장 규모, 예측 및 동향 분석, 2018년에서 2030년까지

제6장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 회사/경쟁 분류
• 벤더 상황
  • 주요 유통업체와 채널 파트너 리스트
  • 주요 고객
  • 주요 시장 점유율 분석, 2022년
  • Abbott
  • Siemens Healthcare GmbH
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Quest Diagnostics Incorporated
  • Danaher
  • Thermo Fisher Scientific, Inc.
  • Hologic Inc.
  • BD
  • Charles River Laboratories
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.

ksm

영문 목차

영문목차

U.S. Molecular Diagnostics Market Growth & Trends:

The U.S. molecular diagnostics market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 4.82% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market growth is attributed to increasing awareness of the benefits of adopting molecular diagnostics tests, such as early and rapid detection of viruses and bacteria. Moreover, the ease of access owing to a well-established healthcare sector coupled with favorable reimbursement policies is anticipated to drive the market growth over the forecast period.

Moreover, prominent players in the industry are investing in the technological advancement of molecular diagnostics techniques to develop solutions capable of reducing human effort and delivering instant results. For instance, QIAGEN launched the EZ2 Connect MDx platform for its application in diagnostic laboratories. The platform is equipped with a high degree of automation to purify RNA & DNA from 24 samples with a turnaround time of 30 minutes.

Developments in rapid detection assays are anticipated to support the market growth. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Numerous players are developing assays and molecular diagnostic systems. Digene HC2 GC-ID DNA test for the diagnosis of Neisseria gonorrhea, & Chlamydia trachomatis by Qiagen and ResistancePlus MG FleXible for the diagnosis of Mycoplasma genitalium with macrolide-resistance identification by Danaher Corporation (Cepheid) are examples of such products.

Major players in the market such as Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc., Hologic Inc., and BD, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in January 2023, Thermo Fisher Scientific and AstraZeneca entered into a collaboration to develop a blood-based and solid tissue companion diagnostic test for Tagrisso.

The COVID-19 pandemic has positively impacted the industry by encouraging players to develop rapid and novel diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

U.S. Molecular Diagnostics Market Report Highlights:

• Based on disease, the respiratory disease segment dominated the market in 2022. The growth is attributed to the increasing prevalence of respiratory infections coupled with the increasing awareness regarding the availability of diagnostic tests for diagnosing and treating infections
• Based on end-use, the hospital core laboratory held the largest share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus
• Major industry players adopt different strategies such as new product launches, collaborations, acquisitions, and expansions to enhance their product penetration and gain a larger consumer base

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Disease
  • 1.1.2. End-use
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease outlook
  • 2.2.2. End-use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Molecular Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
    • 3.4.1.1. Increase in geriatric population
    • 3.4.1.2. Introduction of technologically advanced products
    • 3.4.1.3. Increase in demand for point-of-care testing
    • 3.4.1.4. Growing prevalence of target diseases
    • 3.4.1.5. Increasing external funding for R&D
  • 3.4.2. Market Restraint Analysis
    • 3.4.2.1. Presence of Ambiguous Regulatory Framework
    • 3.4.2.2. High prices of molecular diagnostics tests
• 3.5. U.S. Molecular Diagnostics Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic Landscape
  • 3.5.3. Major Deals & Strategic Alliances Analysis
  • 3.5.4. Market Entry Strategies

Chapter 4. U.S. Molecular Diagnostics Market: Disease Estimates & Trend Analysis

• 4.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.1.1. Healthcare-Associated Infections
    • 4.1.1.1. Methicillin-Resistant Staphylococcus aureus
    • 4.1.1.1.1. Methicillin-Resistant Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.1.2. Staphylococcus aureus
    • 4.1.1.2.1. Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.1.3. Enterovirus
    • 4.1.1.3.1. Enterovirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.1.4. Clostridioides difficile
    • 4.1.1.4.1. Clostridioides difficile market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.1.5. Van A
    • 4.1.1.5.1. Van A market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.1.6. Sepsis Panel
    • 4.1.1.6.1. Sepsis Panel market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.2. Respiratory
    • 4.1.2.1. Flu
    • 4.1.2.1.1. Flu market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.2. Respiratory Syncytial Virus
    • 4.1.2.2.1. Respiratory Syncytial Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.3. Paraflu
    • 4.1.2.3.1. Paraflu market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.4. Multidrug-Resistant Tuberculosis
    • 4.1.2.4.1. Multidrug-Resistant Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.5. Mycobacterium Avium-Intracellular
    • 4.1.2.5.1. Mycobacterium Avium-Intracellulare market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.6. Group A Streptococcal
    • 4.1.2.6.1. Group A Streptococcal market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.7. Adenovirus
    • 4.1.2.7.1. Adenovirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.8. Human Metapneumovirus
    • 4.1.2.8.1. Human Metapneumovirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.9. Rhinoviruses
    • 4.1.2.9.1. Rhinoviruses market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.10. Middle East Respiratory Syndrome Coronavirus
    • 4.1.2.10.1. Middle East Respiratory Syndrome Coronavirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.11. Tuberculosis
    • 4.1.2.11.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.12. Severe Acute Respiratory Syndrome Coronavirus 2
    • 4.1.2.12.1. Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.13. Human Bocavirus-Infection
    • 4.1.2.13.1. Human Bocavirus-Infection market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.14. Bordetella
    • 4.1.2.14.1. Bordetella market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.15. Mycoplasma Pneumonia
    • 4.1.2.15.1. Mycoplasma Pneumonia market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2.16. Respiratory Panels
    • 4.1.2.16.1. Respiratory Panels market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.3. Gastrointestinal
    • 4.1.3.1. Norovirus
    • 4.1.3.1.1. Norovirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.2. Helicobacter pylori
    • 4.1.3.2.1. Helicobacter pylori market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.3. Shiga toxin
    • 4.1.3.3.1. Shiga toxin Market Estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.4. GI Parasite Panel
    • 4.1.3.4.1. GI Parasite Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.5. GI Bacterial Panel
    • 4.1.3.5.1. GI Bacterial Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.6. GI Viral Panel
    • 4.1.3.6.1. GI Viral Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3.7. GI Panels
    • 4.1.3.7.1. GI Panels market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.4. Women's Health/STI
    • 4.1.4.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG)
    • 4.1.4.1.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.2. Trichomonas Vaginalis
    • 4.1.4.2.1. Trichomonas Vaginalis market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.3. Mycoplasma Genitalium
    • 4.1.4.3.1. Mycoplasma genitalium market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.4. Human Papillomavirus
    • 4.1.4.4.1. Human Papillomavirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.5. Bacterial Vaginosis
    • 4.1.4.5.1. Bacterial Vaginosis market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.6. Gonorrhoea Colloquially
    • 4.1.4.6.1. Gonorrhoea Colloquially market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.7. Mycoplasma Genitalium Resistance
    • 4.1.4.7.1. Mycoplasma Genitalium Resistance market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.8. Herpes Simplex Virus
    • 4.1.4.8.1. Herpes Simplex Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4.9. Group B Streptococcus
    • 4.1.4.9.1. Group B Streptococcus market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.5. Immunocompromised
    • 4.1.5.1. Cytomegalovirus
    • 4.1.5.1.1. Cytomegalovirus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5.2. Epstein-Barr virus
    • 4.1.5.2.1. Epstein-Barr virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5.3. Varicella-Zoster Virus
    • 4.1.5.3.1. Varicella-Zoster Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5.4. BK virus
    • 4.1.5.4.1. BK virus market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.6. Virology
    • 4.1.6.1. Human immunodeficiency viruses
    • 4.1.6.1.1. Human immunodeficiency viruses market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6.2. Hepatitis C virus
    • 4.1.6.2.1. Hepatitis C virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6.3. Hepatitis B virus
    • 4.1.6.3.1. Hepatitis B virus Market Estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6.4. Hepatitis E virus
    • 4.1.6.4.1. Hepatitis E virus market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.7. Other Targets
    • 4.1.7.1. Babesia
    • 4.1.7.1.1. Babesia market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.2. Zika
    • 4.1.7.2.1. Zika market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.3. West Nile Virus
    • 4.1.7.3.1. West Nile Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.4. Chikungunya virus/Dengue virus
    • 4.1.7.4.1. Chikungunya virus/Dengue Virus Market Estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.5. Enhancer of zeste homolog 2
    • 4.1.7.5.1. Enhancer of zeste homolog 2 market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.6. PIK3CA
    • 4.1.7.6.1. PIK3CA market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.7. Malaria
    • 4.1.7.7.1. Malaria market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7.8. Monkeypox Virus
    • 4.1.7.8.1. Monkeypox Virus market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.8. Other Panels
    • 4.1.8.1. Meningitis Panel
    • 4.1.8.1.1. Meningitis Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.8.2. Lyme Panel
    • 4.1.8.2.1. Lyme Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.8.3. UTI Panel
    • 4.1.8.3.1. UTI Panel market estimates and forecast 2018 to 2030 (USD Million)
  • 4.1.9. Oncology
    • 4.1.9.1. Microsatellite Instability
    • 4.1.9.1.1. Microsatellite Instability market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9.2. B-raf
    • 4.1.9.2.1. B-raf market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9.3. Epidermal Growth Factor Receptor
    • 4.1.9.3.1. Epidermal Growth Factor Receptor market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9.4. Kirsten Rat Sarcoma Virus
    • 4.1.9.4.1. Kirsten Rat Sarcoma Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9.5. Others
    • 4.1.9.5.1. Others Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. U.S. Molecular Diagnostics Market: End-use Estimates & Trend Analysis

• 5.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.1.1. Hospital Core Laboratory
    • 5.1.1.1. Hospital Core Laboratory market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.2. Hospital Alternative Sites
    • 5.1.2.1. Hospital Alternative Sites market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.3. Decentralized Test Sites
    • 5.1.3.1. Decentralized Test Site market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.4. Reference Lab
    • 5.1.4.1. Reference Lab market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key Company Market Share Analysis, 2022
  • 6.3.4. Abbott
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Siemens Healthcare GmbH
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. QIAGEN
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. F. Hoffmann-La Roche Ltd
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Quest Diagnostics Incorporated
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Danaher
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Thermo Fisher Scientific, Inc.
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Hologic Inc.
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. BD
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives
  • 6.3.13. Charles River Laboratories
    • 6.3.13.1. Company overview
    • 6.3.13.2. Financial performance
    • 6.3.13.3. Product benchmarking
    • 6.3.13.4. Strategic initiatives
  • 6.3.14. Bio-Rad Laboratories, Inc.
    • 6.3.14.1. Company overview
    • 6.3.14.2. Financial performance
    • 6.3.14.3. Product benchmarking
    • 6.3.14.4. Strategic initiatives
  • 6.3.15. Illumina, Inc.
    • 6.3.15.1. Company Overview
    • 6.3.15.2. Financial performance
    • 6.3.15.3. Product benchmarking
    • 6.3.15.4. Strategic initiatives
  • 6.3.16. Agilent Technologies, Inc.
    • 6.3.16.1. Company Overview
    • 6.3.16.2. Financial performance
    • 6.3.16.3. Product benchmarking
    • 6.3.16.4. Strategic initiatives

관련자료